CITI/CALL/MODERNA/240/0.1/20.06.24 | Market Closed - Deutsche Boerse AG 13:27:52 2024-05-31 EDT | ||
| 0.001 EUR | -.--% |
|
| Current year | -95.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 0.001 | -.--% |
| 24-05-30 | 0.001 | -.--% |
| 24-05-29 | 0.001 | -.--% |
| 24-05-28 | 0.001 | -87.50% |
| 24-05-27 | 0.008 | -57.89% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 01:27 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Citi
|
| WKN | KG58AT |
| ISIN | DE000KG58AT9 |
| Date issued | 2022-07-06 |
| Strike | 240 $ |
| Maturity | 2024-06-20 (19 Days) |
| Parity | 10 : 1 |
| Emission price | 2.69 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.75 € |
|---|---|
| Lowest since issue | 0.001 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
142.6
USD
Average target price
139.9
USD
Spread / Average Target
-1.83%
- Stock Market
- Warrants
- Warrant
